Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$28.01
-$0.13(-0.83%)
At close: 4:00 PM EDT
$28.01
-$0.13(-0.83%)
Day’s Range― - ―
52-Week Range$14.19 - $39.18
Previous CloseN/A
Volume4.93M
Average Volume (3M)3.14M
Market Cap
$7.92B
Enterprise Value$4.70K
Total Cash (Recent Filing)$793.12M
Total Debt (Recent Filing)$452.40M
Price to Earnings (P/E)72.1
Beta2.19
Next Earnings
Nov 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding282,595,180
10 Day Avg. Volume3,669,840
30 Day Avg. Volume3,140,012
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)13.19
Price to Sales (P/S)9.38
P/FCF Ratio113.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$26.29Price Target Upside-6.16% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.11
Revenue Forecast (FY)$1.03B
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Clinical-volume GrowthStrong clinical volume, molecular profiling adoption, and higher guidance indicate expanding market penetration. Sustained demand for oncology testing can support durable revenue growth as ordering relationships and clinical use cases broaden.
Improving Margins And Cash GenerationMargin expansion alongside consecutive quarters of positive adjusted EBITDA and free cash flow suggests operating leverage is emerging. If maintained as volumes scale, this can reduce funding needs and improve resilience during product investment.
Proprietary Data And AI Create DifferentiationA large linked clinicogenomic dataset can strengthen test interpretation, drug-development partnerships, and product performance. Its scale and integration with AI may create compounding advantages that are difficult for smaller rivals to replicate.
Bears Say
Persistent GAAP Losses And Uncertain Earnings QualityDespite better EBITDA and cash flow, substantial GAAP losses show that the business has not yet achieved durable bottom-line profitability. Continued losses could constrain returns, obscure underlying economics, and increase execution pressure.
MCED Reimbursement And Evidence RiskUncertain payer, CMS, and FDA outcomes could delay broad adoption of Caris Detect and limit realized revenue from a major growth initiative. Additional evidence requirements for MRD also extend the path from launch to durable reimbursement.
Capacity Expansion And Execution RiskRapid demand growth is positive but creates operational risk if laboratory capacity, inventory, staffing, or suppliers lag. Backorders could defer revenue and weaken customer experience while the company undertakes a large scaling program.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $14.19 and its highest was $39.18 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $7.92B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 76 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Aug 05, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.006 by -$0.006.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Overvalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.03.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,595,180 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0 in its last earnings report, missing expectations of $0.006. Following the earnings report the stock price went up 21.581%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.29 (-6.16% Downside)
$26.29 (-6.16% Downside)
Blogger Sentiment
Bullish
CAI Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 97.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.75%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong operational and financial quarter with substantial year-over-year growth in revenue (+45%), molecular profiling (+55%), and clinical volume (+18%), alongside meaningful margin expansion (GAAP gross margin 68%) and sustained positive adjusted EBITDA and free cash flow. Major product launches (Caris Detect, ChromoSeq, MIClarity V2) and the company’s large proprietary dataset and AI capabilities were highlighted as durable competitive advantages. The primary negatives were operational scaling risks (capacity/backorders), regulatory/reimbursement uncertainty for MCED, MRD evidence-timing uncertainty, and a one-time $25M refinancing charge. Overall, the positives — robust growth, profitability, product launches, and a strong balance sheet — outweigh the manageable execution and timing risks.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$26.29
▼(-6.16% Downside)
Technical Analysis
Bio-Techne
―
Veracyte
―
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
49.13% Insiders
16.19% Mutual Funds
19.80% Other Institutional Investors
7.04% Public Companies and
Individual Investors